AC Immune (ACIU) shares gained more than 12% in premarket trading Thursday after the company said a phase 2 clinical trial of its potential early Parkinson's disease treatment yielded "positive" interim safety and immunogenicity data
The drug candidate, ACI-7104.056, induced antibody responses against the target antigen 16 times higher than the placebo following three immunizations in the 30-patient study, the company said. It added that the treatment showed a positive safety profile.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。